Status: Finalised
First registered on:
11/12/2020
Last updated on:
23/03/2023
1. Study identification
EU PAS Register NumberEUPAS38620
Official titleA Population-based Study of the Safety of Gabapentin Use During Pregnancy
Study title acronymNone
Study typeObservational study
Brief description of the studyThis non-interventional study is being conducted to characterize the use and safety of gabapentin during pregnancy
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
EU RMP category 3 (required)
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicableA9451182
2. Research centres and Investigator details
Coordinating study entity
Centre namePfizer
Centre locationUnited States
Details of (Primary) lead investigator
Title Dr
Last name Kofi
First name Asomaning
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?4
Countries in which this study is being conducted
International study
Denmark
Finland
Norway
Sweden
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed21/12/202021/12/2020
Start date of data collection30/12/202030/12/2020
Start date of data analysis30/04/202130/04/2021
Date of interim report, if expected
Date of final study report31/03/202208/09/2022
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesPfizer Inc100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Kofi
First name Asomaning
Address line 1500 Arcola road
Address line 2
Address line 3
CityCollegeville
PostcodePA 19426
CountryUnited States
Phone number (incl. country code)14848655557
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name Kofi
First name Asomaning
Address line 1500 Arcola road
Address line 2
Address line 3
CityCollegeville
PostcodePA 19426
CountryUnited States
Phone number (incl. country code)14848655557
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)N03AX12 (gabapentin)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Preterm newborns
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Sex
Male
Female
Other population
Pregnant women
9. Number of subjects
Estimated total number of subjects1700
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Prospective patient-based data collection
11. Scope of the study
What is the scope of the study?
Risk assessment
Primary scope : Risk assessment
12. Main objective(s)
What is the main objective of the study?
This non-interventional study is being conducted to characterize the use and safety of gabapentin during pregnancy
Are there primary outcomes?Yes
The primary study outcomes are:
Major congenital malformations (overall and specific);
Stillbirth;
Low birth weight; Small for gestational age;
Preterm birth;
Low Apgar score at 5 minutes;
Microcephaly
Are there secondary outcomes?Yes
The secondary study outcomes are:
Attention-deficit hyperactivity disorders;
Pervasive developmental disorders;
Learning disorders and intellectual disabilities.
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
Follow-up for the postnatal neurodevelopmental outcomes, when available, will be a minimum of 1 year postnatally and for the maximum period available in the dataset for each birth
15. Data analysis plan
Please provide a brief summary of the analysis method
Descriptive statistics (ie, frequency, percent, mean, median, standard deviation as appropriate depending on data type) will be used to summarize demographic and baseline clinical characteristics of patients accrued in the study.
Prevalence of each birth outcome will be computed as the number of newborns with a given outcome divided by the total number of newborns at risk.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documents
DescriptionDocumentLatest version
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
